Cargando…

Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer

BACKGROUND: The recommended phase 2 dose (RP2D) of pamiparib, an investigational PARP1/2 inhibitor, was established as 60 mg twice daily (BID) in a first‐in‐human (FIH) study (NCT02361723). METHODS: Chinese patients with advanced non‐mucinous high‐grade ovarian cancer (HGOC) or triple‐negative breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Binghe, Yin, Yongmei, Dong, Mei, Song, Yan, Li, Wei, Huang, Xiang, Wang, Tongshan, He, Jing, Mu, Xiyan, Li, Li, Mu, Song, Zhang, Wa, Li, Miao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826463/ https://www.ncbi.nlm.nih.gov/pubmed/33128299 http://dx.doi.org/10.1002/cam4.3575

Ejemplares similares

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
por: Wu, Xiaohua, et al.
Publicado: (2022)

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
por: Xu, Binghe, et al.
Publicado: (2022)

OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer
por: Ding, Xiaorong, et al.
Publicado: (2020)

Human Mass Balance and Metabolite Profiling of [(14)C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
por: Mu, Song, et al.
Publicado: (2021)

The transcriptomic profile of ovarian cancer grading
por: Yao, Cindy Q, et al.
Publicado: (2015)

Identification of tRNA‐derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple‐negative breast cancer
por: Feng, Wanting, et al.
Publicado: (2018)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer
por: Li, Yaming, et al.
Publicado: (2019)

Lamin B2 promotes the progression of triple negative breast cancer via mediating cell proliferation and apoptosis
por: Zhao, Cui-Cui, et al.
Publicado: (2021)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
por: Xiong, Yao, et al.
Publicado: (2020)

The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma
por: Yu, Dehao, et al.
Publicado: (2018)

Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report
por: Huang, Xiaoyan, et al.
Publicado: (2022)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma
por: Koh, Iemasa, et al.
Publicado: (2016)

Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay
por: Mateoiu, Constantina, et al.
Publicado: (2021)

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer
por: Wang, Chao‐Qun, et al.
Publicado: (2016)

Early‐onset triple‐negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations
por: Liu, Qian, et al.
Publicado: (2019)

Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer
por: Zhao, Lin, et al.
Publicado: (2020)

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
por: Xu, Yonggang, et al.
Publicado: (2021)

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

Patient perspectives on chemotherapy de‐escalation in breast cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2021)

Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis
por: Weichhaus, Michael, et al.
Publicado: (2014)

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
por: Mu, Song, et al.
Publicado: (2021)

Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer
por: Yao, Yi, et al.
Publicado: (2019)

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
por: Shao, Fengping, et al.
Publicado: (2020)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer
por: Feng, Lanlan, et al.
Publicado: (2020)

Low-Grade Appendiceal Mucinous Neoplasm (LAMN) Primarily Diagnosed as an Ovarian Mucinous Tumor
por: Perivoliotis, Konstantinos, et al.
Publicado: (2021)

Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors
por: Liew, Phui‐Ly, et al.
Publicado: (2018)

Age at menarche and epithelial ovarian cancer risk: A meta‐analysis and Mendelian randomization study
por: Yang, Huijun, et al.
Publicado: (2019)

FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3
por: Xiong, Xifeng, et al.
Publicado: (2022)

A five‐miRNA panel in plasma was identified for breast cancer diagnosis
por: Li, Minghui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uo8uv2kjq7p32oto269go1o8t4